The treatment landscape for EGFR-mutated non-small-cell lung cancer (NSCLC) has significantly evolved with the introduction of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Here, EGFR is linked to non-small cell lung carcinoma.